Trials / Completed
CompletedNCT03232593
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,758 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.
Conditions
- Urothelial Carcinoma
- Carcinoma, Non-Small Cell Lung
- Small Cell Lung Carcinoma
- Triple Negative Breast Carcinoma
- Hepatocellular Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Participants will receive atezolizumab as per the local label and standard of care at physician's discretion. |
Timeline
- Start date
- 2017-11-29
- Primary completion
- 2022-08-12
- Completion
- 2022-08-12
- First posted
- 2017-07-28
- Last updated
- 2022-08-24
Locations
56 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03232593. Inclusion in this directory is not an endorsement.